These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6574296)

  • 21. The pathogenesis of a rat model for human acute myelocytic leukemia.
    Hagenbeek A; Martens AC
    Haematologica; 1980 Jun; 65(3):293-308. PubMed ID: 6778781
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of the distribution pattern of Brown Norway myeloid leukaemia cells and L4415 lymphatic leukaemia cells in rat femoral bone marrow after i.v. infusion.
    Prins ME; van Bekkum DW
    Leuk Res; 1981; 5(1):57-63. PubMed ID: 6939951
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia.
    Martens AC; Hagenbeek A
    Cytometry; 1985 Jul; 6(4):342-7. PubMed ID: 3860369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model.
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):763-9. PubMed ID: 6759141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivariate flow karyotyping of acute myelocytic leukemia in the BNML rat model.
    Arkesteijn GJ; Martens AC; Jonker RR; Hagemeijer A; Hagenbeek A
    Cytometry; 1987 Nov; 8(6):618-24. PubMed ID: 3480794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reinfusion of leukemic cells with the autologous marrow graft: preclinical studies on lodging and regrowth of leukemia.
    Hagenbeek A; Martens AC
    Leuk Res; 1985; 9(11):1389-95. PubMed ID: 3908829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
    Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of tritiated thymidine labeling and suicide indices in acute nonlymphocytic leukemia.
    Preisler H; Shoham D
    Cancer Res; 1978 Nov; 38(11 Pt 1):3681-4. PubMed ID: 279395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia.
    Papiez MA; Dybala M; Sowa-Kucma M; Krzysciak W; Taha H; Jozkowicz A; Nowak G
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):596-604. PubMed ID: 19268504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulation of normal rat bone marrow fibroblast proliferation by sera from leukemic Fischer rats.
    Bauldry SA; Wilson FD; Stromberg PC; Ackerman GA
    Exp Hematol; 1985 Sep; 13(8):750-9. PubMed ID: 4043259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: mathematical considerations.
    Schultz FW; Martens AC; Hagenbeek A
    Leukemia; 1989 Jul; 3(7):530-4. PubMed ID: 2659903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
    Colly LP; van Bekkum DW; Hagenbeek A
    Leuk Res; 1984; 8(6):953-63. PubMed ID: 6595483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).
    Martens AC; van Bekkum DW; Hagenbeek A
    Int J Cell Cloning; 1990 Jan; 8(1):27-38. PubMed ID: 2403582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary tumors after high-dose cyclophosphamide and total-body irradiation followed by bone marrow transplantation in a rat model for human acute myelocytic leukemia (BNML).
    Lopes Cardozo B; Martens AC; Zurcher C; Hagenbeek A
    Eur J Cancer Clin Oncol; 1984 May; 20(5):695-8. PubMed ID: 6329763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of mature leukemic cells in the amplification of leukemic stem cells in a murine model.
    Dührsen U; Knieling G; Hossfeld DK
    Int J Cancer; 1995 Mar; 60(5):652-9. PubMed ID: 7860140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the heterogeneity of minimal residual disease in acute leukemia.
    Hagenbeek A; Martens AC
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():9-12. PubMed ID: 2713565
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term liquid marrow cultures are supported by a mixture of haematopoietic cytokines but do not purge for acute myeloid or lymphoid leukemic marrow cells.
    Johnsen HE; Gaarsdal E; Jensen L; Philip P; Hansen NE
    Leukemia; 1993 Sep; 7(9):1402-8. PubMed ID: 8371591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Leuk Res; 1983; 7(4):547-55. PubMed ID: 6578394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethylene glycol ethers as hemopoietic toxins--in vitro studies of acute exposure.
    Ruchaud S; Boiron O; Cicolella A; Lanotte M
    Leukemia; 1992 Apr; 6(4):328-34. PubMed ID: 1588795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.